Inclusion Criteria:

Stroke Population:

• Ischemic or hemorrhagic stroke in the anterior or posterior circulation within the past month in persons 21 years of age and over
• NIH Stroke Scale Score of 4 or greater one month post-stroke
• Modified Rankin Scale of 2 or greater
• Patients with motor or verbal impairment with surrogacy consent

Inclusion Criteria:

Diabetic Population:

• Clinically stable diabetes type 2 females 21 years of age or older
• Peripheral neuropathy associated with diabetes Dyck stage 2 or 3
• Clinical evaluation by neurologist reveals no other likely cause of neuropathy

Exclusion Criteria:

Stroke Population:

• Men
• Patients with cardiac pacemaker or other indwelling device that would preclude neurophysiologic testing;
• Patients with an indwelling urinary catheter that cannot be removed
• Patients who are on warfarin or similar anticoagulants that cannot be stopped for the study procedures
• Patients with a poor prognosis due to stroke or underlying illness who, it is anticipated, would be unable to participate for the period of the study
• Females with current pregnancy, multiparity >/=4, prior pelvic floor dysfunction, or pelvic floor tumor.

Women with incontinence prior to stroke, cystocele, rectocele, or urethral stricture

• Patients unable to tolerate Detrol LA; such patients would include those with significant renal or hepatic disease, those currently taking drugs metabolized by the cytochrome P450 enzyme system that might confound interpretation of responses ( Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine, ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine, grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin, verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin, St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those with a known sensitivity to the drug or its ingredients
• Patients who have a history of diabetes
• Pregnancy or actively seeking pregnancy
• Patients who are cognitively impaired

Diabetes Population:

Exclusion Criteria:

• Men
• Patients with cardiac pacemaker or other indwelling device that would preclude neurophysiologic testing;
• Patients with an indwelling urinary catheter that cannot be removed
• Patients who are on warfarin or similar anticoagulants that cannot be stopped for the study procedures
• Patients with a poor prognosis due to underlying illness who, it is anticipated, would be unable to participate for the period of the study
• Females with current pregnancy, multiparity >/=4, prior pelvic floor dysfunction, pelvic floor tumor, cystocele, rectocele, or urethral stricture
• Patients unable to tolerate Detrol LA; such patients would include those with significant renal or hepatic disease, those currently taking drugs metabolized by the cytochrome P450 enzyme system that might confound interpretation of responses ( Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine, ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine, grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin, verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin, St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those with a known sensitivity to the drug or its ingredients
• Pregnancy or actively seeking pregnancy